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EDITORIAL
Portugal  at  the  cross  road  of  international  chronic
respiratory programmes
July  1--4,  2015  two  meetings  will  be  held  with  the  Direc-
torate  General  of  Health  in  Lisbon,  Portugal  to  discuss
chronic  respiratory  programmes  of  the  WHO  Global  Alliance
against  Chronic  Respiratory  Diseases  (GARD)1,2 and  Euro-
pean  Innovation  Partnership  on  Active  and  Healthy  Ageing
(EIP  on  AHA)3 (AIRWAYS  ICPs:  Integrated  Care  Pathways  for
airway  diseases).4 The  goals  of  these  meetings  will  be  to
make  an  update  of  these  two  international  actions  and  to
strengthen  the  WHO  noncommunicable  disease  (NCD)  action
plan  (2013--2020).
Chronic  respiratory  diseases  (CRD)  include  asthma,  rhini-
tis  and  COPD,  occupational  lung  diseases,  sleep  apnoea
syndrome  and  genetic  syndromes  such  as  cystic  fibrosis.1,2
Over  1  billion  people  in  the  world  suffer  from  CRDs.  They
represent  one  of  the  priorities  of  the  EU  (3053rd  and  3131st
Conclusions  of  the  EU  Council,  2010  and  2011)5,6 and  the
United  Nations  (High  Level  meeting  on  Non-Communicable
Diseases,  2011).7 The  2011  Polish  Presidence  of  the  EU  Coun-
cil  made  the  prevention,  early  diagnosis  and  treatment  of
asthma  and  allergic  diseases  a  priority  for  the  EU’s  pub-
lic  health  policy  in  order  to  reduce  health  inequalities.5
The  early  determinants  of  CRDs  were  reinforced  during  the
Cyprus  Presidency  of  the  EU  Council.8 The  2014  Italian  Presi-
dence  of  the  EU  Council  has  prioritized  CRDs.  CRDs  represent
a  model  of  chronic  diseases  due  to  their  prevalence,  burden
(3  million  annual  deaths  due  to  COPD),  and  comorbidities
with  other  chronic  diseases.9
European  Innovation  Partnerships  (EIP)  attempt  to
enhance  EU  competitiveness  and  tackle  societal  challenges
by  fostering  innovation.  Active  and  Healthy  Ageing  (AHA)  is
a  major  societal  challenge  common  to  all  countries  and  to
all  populations.10 Ageing,  intertwined  with  socioeconomic
inequalities,  is  an  under-appreciated  cause  of  poverty.  AHA
needs  to  be  promoted  very  early  in  life  to  be  successful.  The
EIP  on  AHA  is  deployed  in  3  areas  and  6  action  plans.11
AIRWAYS  ICPs  (integrated  care  pathways  for  airway  dis-
eases)  has  been  selected  as  the  model  of  NCDs  for  Area
5  of  the  B3  Action  Plan  of  the  EIP  on  AHA  (DG  Sanco  and
DG  CNECT).4 It  was  launched  by  NHS  England  (Newcastle,
February  2014)  and  has  been  endorsed  by  the  EIP  on  AHA
Reference  Site  Network.  The  goals  of  AIRWAYS  ICPs  include
Table  1  Goals  of  AIRWAYS  ICPs.
1.  Proposing  a  common  framework  of  care  pathways  for
chronic  respiratory  diseases  which  will  facilitate
comparability  and  trans-national  initiatives
2. Proposing  plans  targeted  to  all  populations  according  to
culture,  health  systems  and  income
3. Developing  a  strategy  based  on  WHO  PEN  and  the
essential  list  of  drugs  for  low  and  middle  income
countries
4. Informing  cost-effective  policy  development,  in
particular  strengthening  those  on  smoking  and
environment  exposure
5.  Aiding  risk  stratification  in  chronic  disease  patients  with
a common  strategy
6.  Building  a  sentinel  network  for  allergic  diseases  and
asthma
7. Having  a  significant  impact  on  the  health  of  citizens  in
the short  term  (reduction  of  morbidity,  improvement  of
education  in  children  and  of  work  in  adults)  and  the
long-term  (healthy  ageing)
8.  Tackling  chronic  diseases  across  the  life  cycle
9. Defining  active  and  healthy  ageing
10. And  ultimately  reducing  the  healthcare  burden
(emergency  visits,  avoidable  hospitalizations,  disability
and costs)  while  improving  quality  of  life  and  promoting
active and  healthy  ageing.  In  the  longer  term,  the
incidence  of  disease  may  be  reduced  by  innovative
prevention  strategies
the  launch  of  a  collaboration  to  develop  multisectoral  CRD
care  pathways  (ICPs)  in  European  countries  and  regions,  as
part  of  the  EIP  on  AHA  (Area  5  of  the  Action  Plan  B3  of  EIP
on  AHA,  DG  Sanco,  DG  CNECT)  as  well  as  a  global  scale  up
with  WHO  GARD  (GARD  demonstration  research  project).1,2
AIRWAYS-ICPs  has  strategic  relevance  to  the  European  Union
Health  Strategy  and  the  WHO  NCD  Action  Plan  (2013--2020).
The  goals  of  AIRWAYS  ICPs  are  listed  in  Table  1.
Portugal  has  been  promoting  CRDs  for  over  10  years  by  the
scientific  Societies  and,  more  recently,  through  the  National
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Program  on  Respiratory  Diseases,  from  the  Directorate-
General  for  Health.
The  first  meeting  will  review  the  different  actions  of  AIR-
WAYS  ICPs  and  launch  some  activities  which  are  finalized.
Among  them,  a  repository  for  good  practices,  the  new  ARIA
2015  guidelines,  the  MACVIA-ARIA  sentinel  network  and  the
scaling  up  strategy.
Allergic  rhinitis  is  one  of  the  most  prevalent  diseases
in  the  world  (25%  of  the  EU  population).  Although  symp-
toms  of  rhinitis  appear  to  be  trivial,  the  disease  affects
social  activities,  school  and  work  performance  and  allergic
rhinitis  is  associated  with  a  detrimental  effect  on  examina-
tion  performance.12 It  is  often  associated  with  or  precedes
asthma.  Allergic  rhinitis  has  been  considered  to  alter  AHA
if  not  appropriately  managed.5,6 ARIA,  a  guideline  for  aller-
gic  rhinitis  and  its  comorbidity  with  asthma,  was  the  first
comorbidity  guideline  in  chronic  diseases.  It  was  developed
in  the  late  1999s  in  collaboration  with  WHO  using  the  rec-
ommended  methodology  for  guidelines  (Shekelle).13 It  was
updated  in  2008.14 It  has  been  revised  using  the  GRADE
methodology  (2010).15--17 It  is  the  most  widely  used  guideline
for  rhinitis,  and  rhinitis  and  asthma  comorbidity  globally.18
ARIA  is  implemented  in  64  countries  and  the  pocket  guide
of  the  guideline  has  been  translated  into  52  languages.
However,  there  is  a  need  to  develop  a  new  set  of  recommen-
dations  which  will  be  integrated  care  pathways.  The  ARIA
2015  will  be  launched  during  the  meeting  in  Lisbon.
The  MACVIA-ARIA  Sentinel  Network  (MASK)  proposes  to
study  the  symptoms  of  patients  suffering  from  allergic  symp-
toms  during  the  pollen  season  in  order  to  make  them
sentinels  for  the  onset  and  severity  of  the  pollen  season.
Patients  are  geolocalised  and  will  evaluate  their  symptoms
by  visual  analogue  scale  (VAS)  using  a  cell  phone  with  a touch
screen  or  internet.  This  information  will  be  coded  and  sent
to  a  central  database  and  subsequently  to  all  patients  reg-
istered  in  the  system.  A  Clinical  Decision  Support  System
(CDSS)19,20 will  immediately  propose  advice  for  (standard-
ized)  pharmacologic  treatment.  Patients  with  uncontrolled
disease  (SCUAD)21 will  be  easily  defined  as  those  resistant  to
treatment  despite  optimal  treatment.  Moreover,  conjuncti-
val  symptoms  and  asthma  will  be  monitored  by  the  system.
It  will  be  combined  with  CARAT  (Control  of  Allergic  Rhini-
tis  and  Asthma  Test)22,23 in  order  to  better  phenotype  the
patients,  and  an  e-learning  tool.
The  EIP  on  AHA  has  proposed  a  5-step  framework  for
developing  an  individual  scaling  up  strategy:  (1)  what  to
scale  up:  (1--1)  databases  of  good  practices,  (1--2)  assess-
ment  of  viability  of  the  scaling  up  of  good  practices,  (1--3)
classification  of  good  practices  for  local  replication  and  (2)
how  to  scale  up:  (2--1)  facilitating  partnerships  for  scaling
up,  (2--2)  implementation  of  key  success  factors  and  lessons
learnt.  This  strategy  has  already  been  applied  to  the  CRD
action  plan  of  the  EIP  on  AHA.
This  meeting  will  have  the  support  of  the  Région  Langue-
doc  Roussillon24 and  the  Coimbra  Region,  and  will  be  the
third  meeting  of  the  Collaborative  Network  of  EIP  on  AHA
Reference  Sites.
The  second  meeting  will  be  the  GARD  annual  meeting  and
will  review  advances  of  this  WHO  alliance.
Both  meetings  are  supported  by  the  Portuguese  Respi-
ratory  Society  and  show  the  implication  of  this  society  in
international  actions  on  CRDs.
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